CrystalGenomics Inc (083790) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CrystalGenomics Inc (083790) has a cash flow conversion efficiency ratio of -0.129x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-11.39 Billion ≈ $-7.72 Million USD) by net assets (₩87.96 Billion ≈ $59.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CrystalGenomics Inc net asset quality index to measure how much of total assets are equity-financed.
CrystalGenomics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how CrystalGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of CrystalGenomics Inc to evaluate the quality of earnings relative to operating cash generation.
CrystalGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CrystalGenomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STS Group AG
XETRA:SF3
|
0.115x |
|
Neuphoria Therapeutics Inc
NASDAQ:NEUP
|
-0.217x |
|
YSX Tech. Co., Ltd Class A Ordinary Shares
NASDAQ:YSXT
|
-0.250x |
|
Efficient E Solutions Bhd
KLSE:0064
|
-0.011x |
|
Spacenet Enterprises India Limited
NSE:SPCENET
|
0.036x |
|
ClearSign Combustion Corporation
NASDAQ:CLIR
|
-0.135x |
|
Shenzhen Shenbao Industrial Co Ltd
SHE:200019
|
0.124x |
|
Nano Chem Tech Inc
KQ:091970
|
0.077x |
Annual Cash Flow Conversion Efficiency for CrystalGenomics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of CrystalGenomics Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 083790 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩98.52 Billion ≈ $66.76 Million |
₩-25.85 Billion ≈ $-17.52 Million |
-0.262x | -17.63% |
| 2023-12-31 | ₩145.29 Billion ≈ $98.46 Million |
₩-32.41 Billion ≈ $-21.96 Million |
-0.223x | -72.08% |
| 2022-12-31 | ₩188.28 Billion ≈ $127.59 Million |
₩-24.40 Billion ≈ $-16.54 Million |
-0.130x | -135.12% |
| 2021-12-31 | ₩207.84 Billion ≈ $140.85 Million |
₩-11.46 Billion ≈ $-7.77 Million |
-0.055x | +27.74% |
| 2020-12-31 | ₩214.76 Billion ≈ $145.54 Million |
₩-16.38 Billion ≈ $-11.10 Million |
-0.076x | -59.32% |
| 2019-12-31 | ₩149.05 Billion ≈ $101.01 Million |
₩-7.14 Billion ≈ $-4.84 Million |
-0.048x | -632.04% |
| 2018-12-31 | ₩184.47 Billion ≈ $125.01 Million |
₩-1.21 Billion ≈ $-817.78K |
-0.007x | -136.69% |
| 2017-12-31 | ₩91.59 Billion ≈ $62.07 Million |
₩1.63 Billion ≈ $1.11 Million |
0.018x | +117.86% |
| 2016-12-31 | ₩83.16 Billion ≈ $56.36 Million |
₩-8.30 Billion ≈ $-5.63 Million |
-0.100x | -51.96% |
| 2015-12-31 | ₩71.94 Billion ≈ $48.75 Million |
₩-4.73 Billion ≈ $-3.20 Million |
-0.066x | +3.72% |
| 2014-12-31 | ₩55.03 Billion ≈ $37.29 Million |
₩-3.75 Billion ≈ $-2.54 Million |
-0.068x | -- |
About CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more